Provided by Tiger Fintech (Singapore) Pte. Ltd.

Quince Therapeutics, Inc.

1.17
-0.0200-1.68%
Post-market: 1.170.00000.00%19:58 EDT
Volume:191.24K
Turnover:228.17K
Market Cap:53.20M
PE:-0.84
High:1.21
Open:1.20
Low:1.16
Close:1.19
Loading ...

Quince Therapeutics Inc. Held Annual Stockholder Meeting Online

Reuters
·
Yesterday

Quince Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
04 Jun

Quince Therapeutics Says Enrollment for Phase 3 Clinical Trial in Ataxia-Telangiectasia Exceeds 75%

MT Newswires Live
·
04 Jun

Quince Therapeutics tops 75% enrollment in pivotal Phase 3 NEAT clinical trial

TIPRANKS
·
04 Jun

Quince Therapeutics Granted FDA Fast Track Designation for eDSP System in Treating Ataxia-Telangiectasia

Reuters
·
04 Jun

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 Neat Clinical Trial in Ataxia-Telangiectasia

THOMSON REUTERS
·
04 Jun

Maxim Group Sticks to Its Buy Rating for Quince Therapeutics (QNCX)

TIPRANKS
·
15 May

Quince Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Quince Therapeutics Inc - Plans Early Enrollment Conclusion for Phase 3 Neat Trial - SEC Filing

THOMSON REUTERS
·
13 May

Quince Therapeutics Inc - Reports $15 Million Net Loss, $0.34 per Share for Q1 2025 - SEC Filing

THOMSON REUTERS
·
13 May

Quince Therapeutics Q1 EPS USD -0.34

THOMSON REUTERS
·
13 May

Quince Therapeutics Reports Q1 2025 Net Loss of $15 Million, EPS at -$0.34

Reuters
·
13 May

Quince Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
09 May

Quince Therapeutics to Present at Citizens Life Sciences Conference

Business Wire
·
01 May

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Business Wire
·
04 Apr

BRIEF-Quince Therapeutics Files For Common Stock Offering Of Up To $21.9 Million - SEC Filing

Reuters
·
25 Mar

Quince Therapeutics Files for Common Stock Offering of up to $21.9 Mln - SEC Filing

THOMSON REUTERS
·
25 Mar

BRIEF-Quince Therapeutics Existing Cash Position To Provide Operating Runway Through Phase 3 Topline Results Into 2026

Reuters
·
25 Mar

Quince Therapeutics: Existing Cash Position to Provide Operating Runway Through Phase 3 Topline Results Into 2026

THOMSON REUTERS
·
25 Mar

Press Release: Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Dow Jones
·
25 Mar